BiotechTube

Ramucirumab + Paclitaxel + Placebo

Phase 3Completed
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Junction Adenocarcinoma

Conditions

Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

Trial Timeline

Mar 2, 2017 → Apr 12, 2021

NCT ID
NCT02898077

About Ramucirumab + Paclitaxel + Placebo

Ramucirumab + Paclitaxel + Placebo is a phase 3 stage product being developed by Eli Lilly for Gastroesophageal Junction Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02898077. Target conditions include Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma.

What happened to similar drugs?

4 of 20 similar drugs in Gastroesophageal Junction Adenocarcinoma were approved

Approved (4) Terminated (1) Active (16)
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
🔄zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
🔄E3810 + E3810 + PlaceboEisaiPhase 3
🔄Rabeprazole ER + RanitidineEisaiPhase 3
✅rabeprazole and pantoprazoleEisaiApproved
🔄RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02898077Phase 3Completed

Competing Products

20 competing products in Gastroesophageal Junction Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
FamotidineAstellas PharmaPhase 2/3
38
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
E3810 + E3810 + PlaceboEisaiPhase 3
40
Rabeprazole ER + RanitidineEisaiPhase 3
40
E3710 + E3710EisaiPhase 1
29
rabeprazole and pantoprazoleEisaiApproved
43
Rabeprazole 20 mgEisaiPhase 2
35
rabeprazole sodiumEisaiPhase 2
35
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
40
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Rabeprazole + Rabeprazole + Rabeprazole + RabeprazoleEisaiPhase 3
40